The city of Los Angeles, California, currently has 90 active clinical trials seeking participants for Breast Cancer research studies.
Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer
NCT05318469
Recruiting
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growth... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Register for Updates
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
NCT05511844
Recruiting
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: University of California - Los Angeles, Los Angeles, California
Conditions: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Register for Updates
Breast Cancer Survivorship Biorepository
NCT05786664
Recruiting
This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Register for Updates
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT03804944
Recruiting
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.
Gender:
Female
Ages:
Between 18 years and 90 years
Trial Updated:
03/22/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Breast Cancer
Register for Updates
Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis
NCT02735746
Recruiting
The purpose of this study is to to compare lung function data generated by applying High Fidelity Functional Lung Imaging (HFFLI) software to 4D CT, cone beam CT, and fluoroscopic images of the lungs breathing to determine whether different modalities of imaging provide similar data on lung movement and function. HFFLI may detect changes in lung function in patients undergoing External Beam Radiotherapy for cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Lung Cancer, Breast Cancer, Mediastinum Lesion, Radiation Pneumonitis
Register for Updates
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT05491226
Recruiting
This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients with high-risk TNBC. The primary objective is to assess the pathologic complete response (pCR) rate where pCR is defined as the absence of invasive disease in the breast and lymph nodes at the time of standard of care (SOC) treatment. Secondary objectives include evaluating the change in tumor infiltrating lymphocytes (TILs), safety and to... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Register for Updates
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512
Recruiting
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Research Site, Los Angeles, California
Conditions: Breast Cancer
Register for Updates
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
NCT04593277
Recruiting
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Register for Updates
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039
Recruiting
This study evaluates the safety and effectiveness of the da Vinci SP Surgical System compared to Open NSM in Nipple Sparing Mastectomy procedures.
Gender:
Female
Ages:
21 years and above
Trial Updated:
03/07/2024
Locations: Cedars-Sinai, Los Angeles, California
Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Register for Updates
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT04542135
Recruiting
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Gender:
Female
Ages:
Between 35 years and 70 years
Trial Updated:
03/06/2024
Locations: Cedars Sinai - Cancer, Los Angeles, California
Conditions: Breast Cancer
Register for Updates
A Culturally Sensitive Social Support Intervention
NCT02946697
Recruiting
This study is a randomized controlled trial (RCT) to assess the impact of a culturally based social support program (i.e. Joy Luck Academy, JLA) among Chinese American breast cancer survivors.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Herald Cancer Association, Los Angeles, California
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574
Recruiting
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: NGM Clinical Study Site, Los Angeles, California
Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Register for Updates